Published in J Virol on December 01, 1999
Estimating mutation parameters, population history and genealogy simultaneously from temporally spaced sequence data. Genetics (2002) 10.63
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol (2005) 7.91
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Smooth skyride through a rough skyline: Bayesian coalescent-based inference of population dynamics. Mol Biol Evol (2008) 6.52
Viral population estimation using pyrosequencing. PLoS Comput Biol (2008) 5.89
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol (2003) 4.56
Evolutionary analysis of the dynamics of viral infectious disease. Nat Rev Genet (2009) 4.56
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol (2002) 3.38
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol (2006) 2.97
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol (2005) 2.89
Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
Pervasive genomic recombination of HIV-1 in vivo. Genetics (2004) 2.79
Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol (2002) 2.71
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe (2011) 2.59
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS (2009) 2.55
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog (2007) 2.38
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol (2004) 2.33
Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol (2008) 2.32
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
HIV-1 group M conserved elements vaccine. PLoS Pathog (2007) 2.28
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLoS Comput Biol (2007) 2.25
Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol (2002) 2.19
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog (2011) 2.13
Estimation of 2Nes from temporal allele frequency data. Genetics (2008) 2.12
Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol Mol Biol Rev (2001) 2.06
Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis (2008) 2.01
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol (2006) 2.00
Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96
Fast, accurate and simulation-free stochastic mapping. Philos Trans R Soc Lond B Biol Sci (2008) 1.90
Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS (2011) 1.88
HIV and the chemokine system: 10 years later. EMBO J (2006) 1.88
DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites. Biotechniques (2010) 1.88
Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol (2003) 1.83
Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J Virol (2006) 1.82
Modeling the site-specific variation of selection patterns along lineages. Proc Natl Acad Sci U S A (2004) 1.82
Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol (2005) 1.77
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77
Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol (2002) 1.75
Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci U S A (2005) 1.75
Recombination rate and selection strength in HIV intra-patient evolution. PLoS Comput Biol (2010) 1.73
Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1. J Virol (2007) 1.71
HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis (2008) 1.70
Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis (2009) 1.67
Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol (2010) 1.66
Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol (2010) 1.65
Evolutionary fingerprinting of genes. Mol Biol Evol (2009) 1.64
Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis (2011) 1.64
Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol (2003) 1.62
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med (2012) 1.61
HIV-specific probabilistic models of protein evolution. PLoS One (2007) 1.61
Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection. Blood (2012) 1.60
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Using temporally spaced sequences to simultaneously estimate migration rates, mutation rate and population sizes in measurably evolving populations. Genetics (2004) 1.57
HIV-1 transmission during early infection in men who have sex with men: a phylodynamic analysis. PLoS Med (2013) 1.55
Characterizing HIV transmission networks across the United States. Clin Infect Dis (2012) 1.54
Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J Virol (2005) 1.53
Simple epidemiological dynamics explain phylogenetic clustering of HIV from patients with recent infection. PLoS Comput Biol (2012) 1.51
Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol (2001) 1.51
Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J Virol (2002) 1.50
Comparison of methods to detect HIV dual infection. AIDS Res Hum Retroviruses (2010) 1.47
Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One (2011) 1.46
Minority variants of drug-resistant HIV. J Infect Dis (2010) 1.44
Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol (2012) 1.44
New insights into the evolutionary rate of HIV-1 at the within-host and epidemiological levels. Proc Biol Sci (2012) 1.43
The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology (2011) 1.42
Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol (2005) 1.42
Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol (2011) 1.41
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS (2009) 1.40
Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J Virol (2000) 1.39
Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput Biol (2008) 1.39
Estimation of effective population size of HIV-1 within a host: a pseudomaximum-likelihood approach. Genetics (2002) 1.38
Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. Virology (2008) 1.38
Bayesian inference of sampled ancestor trees for epidemiology and fossil calibration. PLoS Comput Biol (2014) 1.38
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest (2001) 1.38
A simple method for finding explicit analytic transition densities of diffusion processes with general diploid selection. Genetics (2011) 1.37
Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain. J Virol (2005) 1.36
A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol (1980) 113.75
The detection of disease clustering and a generalized regression approach. Cancer Res (1967) 39.90
MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers. Comput Appl Biosci (1994) 28.25
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 11.21
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 10.35
Recent advances in the polymerase chain reaction. Science (1991) 9.98
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A (1997) 8.27
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science (1996) 7.73
Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 7.59
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med (1995) 6.90
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med (1995) 6.26
HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr (1989) 6.16
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Severe premature coronary artery disease with protease inhibitors. Lancet (1998) 5.59
A new classification for HIV-1. Nature (1998) 5.30
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol (1997) 5.18
Antigenic diversity thresholds and the development of AIDS. Science (1991) 5.13
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
HIV quasispecies and resampling. Science (1996) 3.98
Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med (1997) 3.71
Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat Med (1995) 3.46
HIV entry and tropism: the chemokine receptor connection. AIDS (1997) 3.32
Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet (1998) 3.22
Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci U S A (1992) 3.19
The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis (1994) 3.16
Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature (1998) 3.02
Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays. AIDS Res Hum Retroviruses (1997) 2.91
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci U S A (1990) 2.78
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol (1997) 2.72
Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J Clin Invest (1997) 2.69
Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J Virol (1989) 2.62
Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol (1990) 2.50
Tempo and mode of nucleotide substitutions in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history. J Virol (1997) 2.47
High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest (1998) 2.47
Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol (1998) 2.21
Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. J Virol (1997) 2.16
Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol (1997) 2.11
Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry (1993) 2.07
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol (1995) 2.06
Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J Virol (1997) 2.04
Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.99
Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J Virol (1994) 1.87
Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol (1994) 1.85
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology (1994) 1.85
Matrix correlation tests support a single origin for modern humans. Nature (1994) 1.79
Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci U S A (1998) 1.72
CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. J Virol (1998) 1.72
CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation. J Immunol (1998) 1.64
Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo. J Virol (1997) 1.63
Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.61
Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology (1998) 1.57
In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. J Virol (1997) 1.48
The incubation period of AIDS. AIDS (1997) 1.47
Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression. J Virol (1995) 1.43
Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function. J Virol (1997) 1.30
Anti-HIV type 1 memory cytotoxic T lymphocyte responses associated with changes in CD4+ T cell numbers in progression of HIV type 1 infection. AIDS Res Hum Retroviruses (1998) 1.23
Primary subtype C HIV-1 infection in Harare, Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.22
Identification of inflections in T-cell counts among HIV-1-infected individuals and relationship with progression to clinical AIDS. Proc Natl Acad Sci U S A (1998) 1.14
Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease. J Virol (1997) 1.10
HIV type 1 V3 variation dynamics in vivo: long-term persistence of non-syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS. AIDS Res Hum Retroviruses (1997) 1.09
Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution. J Virol (1999) 1.04
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 37.15
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
LDL-receptor-related proteins in Wnt signal transduction. Nature (2000) 6.94
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med (1995) 6.90
HIV-1 nomenclature proposal. Science (2000) 6.61
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol (2001) 5.95
Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol (1997) 5.94
Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis (2001) 5.43
Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell (1986) 5.35
Photonic detection of bacterial pathogens in living hosts. Mol Microbiol (1995) 5.24
Sex differences in HIV-1 viral load and progression to AIDS. Lancet (1998) 5.24
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Likelihood-based tests of topologies in phylogenetics. Syst Biol (2000) 4.34
Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet (1987) 4.33
Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1. Cell (2001) 4.22
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med (1996) 4.13
HIV quasispecies and resampling. Science (1996) 3.98
Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood (2001) 3.90
Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73
The genome organization of STLV-3 is similar to that of the AIDS virus except for a truncated transmembrane protein. Cell (1987) 3.65
Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. Nature (1990) 3.54
Viral transduction of c-myc gene in naturally occurring feline leukaemias. Nature (1984) 3.39
Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med (1994) 3.32
The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med (1992) 3.32
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia (2000) 3.32
Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med (2000) 3.30
Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis (1992) 3.27
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
I-POU: a POU-domain protein that inhibits neuron-specific gene activation. Nature (1991) 3.15
Molecular epidemiology of HIV transmission in a dental practice. Science (1992) 3.10
SIV adaptation to human cells. Nature (1989) 3.09
Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis (2007) 3.00
Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays. Virology (2000) 2.92
Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays. AIDS Res Hum Retroviruses (1997) 2.91
Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats. Science (1988) 2.86
Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A (1999) 2.85
Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene (2010) 2.73
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol (1997) 2.72
Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68
Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med (2001) 2.68
beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci U S A (1999) 2.66
Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation (1996) 2.64
Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses. J Virol (1988) 2.62
Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. Nature (1987) 2.61
Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion (1995) 2.60
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature (1998) 2.56
Use of a colorimetric system for yeast susceptibility testing. J Clin Microbiol (1995) 2.54
Disease-specific and tissue-specific production of unintegrated feline leukaemia virus variant DNA in feline AIDS. Nature (1986) 2.52
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
Dopamine infusion: a simpler formula. Indian Pediatr (1994) 2.51
Isolation and characterization of new fission yeast cytokinesis mutants. Genetics (1998) 2.51
Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol (1990) 2.50
Extending the range of rate constants available from BIACORE: interpreting mass transport-influenced binding data. Biophys J (1998) 2.49
Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS (1996) 2.49
Opportunistic lung infection due to "Pittsburgh Pneumonia Agent". N Engl J Med (1979) 2.49
Antibodies to cell membrane antigens associated with human T-cell leukemia virus in patients with AIDS. Science (1983) 2.48
Detection of hepatitis-B surface antigen in blood and blood products dried on filter paper. Lancet (1978) 2.48
Detecting antibodies to human immunodeficiency virus in dried blood on filter papers. J Infect Dis (1987) 2.47
Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity (1998) 2.46
Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis (1998) 2.46
New bacterial agent of pneumonia isolated from renal-transplant recipients. Lancet (1979) 2.45
Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic western blot. Evidence from a cohort of homosexual men. Ann Intern Med (1989) 2.44
Mechanisms of immunosuppression in cytomegaloviral mononucleosis. J Infect Dis (1980) 2.41
Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA (1998) 2.37
Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad Sci U S A (1997) 2.36
Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses. J Virol (1986) 2.34
Interaction of cytomegalovirus with leukocytes from patients with mononucleosis due to cytomegalovirus. J Infect Dis (1977) 2.30
Limbal stem cell deficiency: concept, aetiology, clinical presentation, diagnosis and management. Indian J Ophthalmol (2000) 2.28
Genes involved in senescence and immortalization. Curr Opin Cell Biol (2000) 2.27
Variables influencing condom use in a cohort of gay and bisexual men. Am J Public Health (1988) 2.26
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis (1994) 2.26
Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis (2000) 2.25
Nucleotide sequence of the envelope gene of Gardner-Arnstein feline leukemia virus B reveals unique sequence homologies with a murine mink cell focus-forming virus. J Virol (1983) 2.24
Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol (1998) 2.21